TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03230721

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium-fiber laser enucleation of the prostate
Description: A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar enucleation of the prostate
Description: Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ho:YAG laser enucleation of the prostate
Description: Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
Study: NCT02425280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study: NCT03915366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir Oral Solution [Valcyte]
Description: Treatment for CMV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuberculostatic Agents
Description: Treatment for tuberculosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuberculostatic Agents
Description: Treatment for tuberculosis
Study: NCT02257463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral muscles exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral muscles exercise training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory muscle training
Description: Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
Study: NCT03206580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric training
Description: Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric-Eccentric training
Description: Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
Study: NCT01995266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study: NCT03288454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 10mg given twice daily (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 10mg given twice daily (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 10mg given twice daily (q12h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apixaban
Description: Apixaban 10mg given twice daily (q12h)
Study: NCT02623777

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan oligosaccharides
Description: Arabinoxylan oligosaccharides administered

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan oligosaccharides
Description: Arabinoxylan oligosaccharides administered

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short chain fatty acids
Description: Short chain fatty acids administered

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short chain fatty acids
Description: Short chain fatty acids administered
Study: NCT00618735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB021
Description: Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB021
Description: Twice daily dosing
Study: NCT02318836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine Hydrochloride (HCl) tablets
Description: Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine Hydrochloride (HCl) tablets
Description: Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine Hydrochloride (HCl) tablets
Description: Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine Hydrochloride (HCl) tablets
Description: Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
Study: NCT01018654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cognitive Behavioral Treatment
Description: Standard CBT for Substance Abuse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive-Behavioral Treatment
Description: Culturally Adapted CBT for Substance Abuse
Study: NCT04648332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: compartment psoas block
Study: NCT04923698

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: yoga training
Description: All women in group B were treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: yoga training
Description: All women in group B were treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
Study: NCT01618526

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Western Style Diet
Description: Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Carbohydrate Diet
Description: Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
Study: NCT00637377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Description: Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Description: Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Description: Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Study: NCT04843969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress induction
Description: Exposure to a psychosocial stressor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress induction
Description: Exposure to a psychosocial stressor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control stress exposure
Description: Exposure to a control task (no stress)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control stress exposure
Description: Exposure to a control task (no stress)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue induction
Description: Exposure to a smoking-related task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue induction
Description: Exposure to a smoking-related task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral cue exposure
Description: Exposure to neutral cues

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral cue exposure
Description: Exposure to neutral cues
Study: NCT01939964

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activation Mist
Description: Activation Mist topical spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Activation Mist
Description: Activation Mist topical spray
Study: NCT03205436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affinity human amniotic membrane
Description: fresh hypothermically stored human amniotic membrane
Study: NCT02477605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONSTELLATION® 27-gauge Combined Surgical Pak
Description: Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONSTELLATION® 23-gauge Combined Surgical Pak
Description: Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy surgery
Description: Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy surgery
Description: Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
Study: NCT03721913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participation-based intervention
Description: The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
Study: NCT03419572

Intervention type: OTHER
Intervention: Data collection
Description: Only available evaluations as decided by the investigator based on local clinical practice will be collected.

Intervention type: OTHER
Intervention: Data collection
Description: Only available evaluations as decided by the investigator based on local clinical practice will be collected.
Study: NCT00198315

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Medpulser electroporation with Bleomycin
Description: Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
Study: NCT03041883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crosslinking with riboflavin of the corneal graft-support
Description: Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: De-epithelisation of the corneal graft support with instillation of riboflavin
Description: Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
Study: NCT03019575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight \>60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
Study: NCT00198315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumor surgical excision
Description: Patients have their tumor surgically removed.
Study: NCT00593866

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: INTENSITY MODULATED RADIOTHERAPY
Description: Five fractions weekly, fraction size determined by dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
Study: NCT02965846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263
Description: 1 drop of AGN-195263 will be instilled in each eye twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
Study: NCT01388361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily. The doses will be individually adjusted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily. The doses will be individually adjusted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected s.c. (under the skin) once daily. The doses will be individually adjusted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected s.c. (under the skin) once daily. The doses will be individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
Study: NCT03366701

Intervention type: OTHER
Intervention: Rehabilitation
Description: The intervention (routine care) correspond to five weeks rehabilitation program

Intervention type: OTHER
Intervention: Rehabilitation
Description: The intervention (routine care) correspond to five weeks rehabilitation program
Study: NCT02717117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soup meal
Description: Soup meal as above
Study: NCT00355095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: intravenous daily 3.3 \*10\^4 Units, duration 3 days
Study: NCT02764242

Intervention type: OTHER
Group type: OTHER
Intervention: Skin prick test
Description: Skin prick tests to local and imported insect sting allergen with different concentration are performed.

Intervention type: OTHER
Group type: OTHER
Intervention: sIgE measurement
Description: sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
Study: NCT03837886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
Study: NCT02715544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle
Description: The families will receive a designed for these purposes intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity and dietary guidelines
Description: The families will receive a designed for these purposes intervention
Study: NCT04477772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
Study: NCT03035396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diassess Influenza A and B Test
Study: NCT01350024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine
Description: Frontal Nerve Block 5 cc will be administered preoperatively once.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine
Description: Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
Study: NCT02938754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based motor training
Description: Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
Study: NCT03758404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adeno-associated virus vector AAV- CNGA3
Description: Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adeno-associated virus vector AAV- CNGA3
Description: Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adeno-associated virus vector AAV- CNGA3
Description: Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene
Study: NCT01513382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pilonidal sinus excision
Description: The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
Study: NCT03641391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative direct cortical electrical stimulation
Description: Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative direct subcortical electrical stimulation
Description: Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
Study: NCT01087632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Armolipid Plus
Description: Armolipid Plus 1 tablet QD for 18 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Armolipid Plus
Description: Armolipid Plus 1 tablet QD for 18 weeks
Study: NCT02595268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
Study: NCT02856906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occlusal adjustment
Study: NCT04583761

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
Study: NCT00599235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: 50mg 3 times daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: 50mg 3 times daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydralazine
Description: 25mg 3 times daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydralazine
Description: 25mg 3 times daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 3 times daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 3 times daily for 7 days